Last Updated: May 1, 2026

CLINICAL TRIALS PROFILE FOR EZETIMIBE AND SIMVASTATIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ezetimibe And Simvastatin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079638 ↗ Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL Completed Kos Pharmaceuticals Phase 4 2004-04-01 The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.
NCT00090298 ↗ Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058) Completed Merck Sharp & Dohme Corp. Phase 3 2004-04-01 A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
NCT00092599 ↗ Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801) Completed Merck Sharp & Dohme Corp. Phase 3 2003-02-01 This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
NCT00092612 ↗ Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-05-01 The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ezetimibe And Simvastatin

Condition Name

Condition Name for Ezetimibe And Simvastatin
Intervention Trials
Hypercholesterolemia 48
Atherosclerosis 14
Hyperlipidemia 7
Coronary Heart Disease 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ezetimibe And Simvastatin
Intervention Trials
Hypercholesterolemia 55
Coronary Disease 17
Coronary Artery Disease 17
Atherosclerosis 16
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ezetimibe And Simvastatin

Trials by Country

Trials by Country for Ezetimibe And Simvastatin
Location Trials
United States 77
Brazil 10
Mexico 8
Spain 6
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ezetimibe And Simvastatin
Location Trials
California 5
Texas 5
New York 5
Michigan 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ezetimibe And Simvastatin

Clinical Trial Phase

Clinical Trial Phase for Ezetimibe And Simvastatin
Clinical Trial Phase Trials
PHASE2 2
Phase 4 40
Phase 3 42
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ezetimibe And Simvastatin
Clinical Trial Phase Trials
Completed 85
Unknown status 11
Terminated 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ezetimibe And Simvastatin

Sponsor Name

Sponsor Name for Ezetimibe And Simvastatin
Sponsor Trials
Merck Sharp & Dohme Corp. 64
Schering-Plough 6
University of Sao Paulo 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ezetimibe And Simvastatin
Sponsor Trials
Industry 80
Other 71
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ezetimibe And Simvastatin Market Analysis and Financial Projection

Last updated: April 30, 2026

EZETIMIBE + SIMVASTATIN: Clinical Trials Update, Market Analysis, and Projection

What is EZETIMIBE + SIMVASTATIN (fixed-dose) and how is it positioned clinically?

Ezetimibe plus simvastatin is a lipid-lowering combination used to treat primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia, with the goal of lowering LDL-C and other atherogenic lipids. The fixed-dose combination is marketed as a dose-titrated regimen that pairs ezetimibe, which reduces intestinal cholesterol absorption, with simvastatin, which inhibits hepatic cholesterol synthesis.

Core clinical rationale

  • Mechanism complementarity: ezetimibe targets absorption; simvastatin targets synthesis.
  • Dose strategy: simvastatin provides potent LDL-C reduction; ezetimibe adds incremental LDL-C lowering at lower statin intensities than monotherapy escalation.

Regulatory status (product class)

  • The combination is an established, post-approval therapy class with mature labeling and commercial uptake. There is no indication from public sources that it is moving through a new pivotal program as a combination new molecular entity; most activity typically concentrates on line extensions, label refinements, and post-marketing commitments rather than new registrational endpoints.

What is the current clinical trials update for EZETIMIBE + SIMVASTATIN?

Public registries for combination therapies generally show (a) low incidence of new phase 3 trials using fixed-dose ezetimibe/simvastatin as the primary investigational regimen, and (b) more frequent studies that are either:

  • post-marketing observational studies,
  • pharmacokinetic (PK) or bioequivalence (BE) work,
  • comparative effectiveness studies using real-world datasets,
  • adherence or switching studies (e.g., persistence on therapy, dose optimization).

Clinical-trial “signal” in the open literature and registries

  • The combination is widely studied historically, but new registrational phase 2/3 activity is not a dominant pattern in recent years versus continuing post-approval evidence generation.
  • Current activity is typically incremental rather than program-defining, meaning trial counts exist but they rarely drive a new commercialization step-change.

Implication for R&D planning

  • For investment or development strategy, EZETIMIBE + SIMVASTATIN should be treated as a mature combination unless a specific, clearly registrational program is identified in a given geography for a specific formulation or new indication. Without a named, ongoing phase 3 program (registered with endpoints, timelines, and sites) for the combination as a fixed-dose therapy, the near-term clinical update is best characterized as post-approval evidence maintenance rather than late-stage expansion.

How does the market currently price and compete EZETIMIBE + SIMVASTATIN?

The combination competes in a crowded cholesterol-lowering landscape that includes:

  • high-intensity statins and statin/ezetimibe equivalents,
  • PCSK9 inhibitors (injectables),
  • bile acid sequestrants,
  • newer oral lipid agents in some segments.

Competitive structure

  • Ezetimibe/statins compete on tolerability, oral administration, and incremental LDL-C.
  • They face margin pressure from generic statins, generic ezetimibe, and generic combination tablets where available.
  • Uptake is sensitive to formulary positioning and managed care contracting.

Commercial reality

  • Fixed-dose products often maintain demand through:
    • formulary preference for combination pills,
    • lower treatment cost versus injectables,
    • clinician familiarity.
  • Growth is constrained by:
    • generic erosion,
    • substitution toward other combination regimes (e.g., different statin/ezetimibe pairings, or newer lipid therapies when payer coverage supports them).

What is the market size and growth outlook for EZETIMIBE + SIMVASTATIN (global and major markets)?

A precise global market forecast for this exact fixed-dose combination requires product-level sales data and geography-level formulary splits, which are not reliably available in a consistent, open source format. Publicly accessible market commentary for lipid-lowering drugs is generally reported at the class level (statins, ezetimibe, statin combinations, or broader LDL-C lowering categories), not always for the fixed-dose combination “EZETIMIBE + SIMVASTATIN” as a separately tracked SKU.

Given that limitation, the business-grade approach is to project using class and competitive dynamics:

  • The ezetimibe/statin segment is supported by:
    • persistent large prevalent population with hypercholesterolemia,
    • clinician adoption of oral combination therapy to intensify treatment without switching to injectables.
  • The ceiling is set by:
    • generic substitution,
    • payer preference shifts as newer agents gain coverage.

Directional projection (treat as a class-weighted forecast for ezetimibe/statin products)

  • Base case: modest growth or flat-to-slight decline in some regions due to generics, offset by continued new patient starts and adherence benefits of fixed-dose combination.
  • Upside case: incremental share gain where payers require oral step therapy before costly injectables.
  • Downside case: accelerated switching to alternative oral combinations (where available) or greater access to PCSK9 inhibitors under negotiated pricing.

Where are the biggest commercial risks and opportunities?

Risk drivers

  • Generic pressure: fixed-dose tablet economics typically compress quickly once generic equivalents are established in key markets.
  • Payer switching: if managed care favors other LDL-C regimens for cost-effectiveness, ezetimibe/statin share can erode even while overall lipid-treated prevalence increases.
  • Competing oral regimens: alternative statin/ezetimibe pairings and other LDL-C therapies can displace fixed-dose combinations if they offer better dosing simplicity or negotiated pricing.

Opportunity drivers

  • Formulary step therapy: combination tablets are often used as an intermediate intensification step before injectables.
  • Adherence and persistence: fixed-dose regimens can improve adherence versus loose dosing schedules, which matters for payer outcome programs.
  • Real-world performance evidence: observational outcomes that demonstrate LDL-C control and persistence can support formulary retention.

What does the projection timeline look like across the patent and competitive cycle?

For established ezetimibe/statin fixed-dose products, the commercialization timeline is dominated less by pipeline substitution and more by:

  • format and supply chain consolidation,
  • generic entry waves across regions,
  • contracting and rebate dynamics with payers.

Practical timeline logic

  • Near term (0 to 24 months): stable demand patterns, with volume supported by prevalence and clinician prescribing habits; revenue may track slightly down in markets where generics expand faster.
  • Mid term (2 to 5 years): stronger effect from payer contracting and displacement by other LDL-C options (especially when coverage criteria relax for injectables).
  • Long term (5+ years): continued class stability is plausible, but fixed-dose brand economics depend heavily on generic share dynamics and competitive formulary choices.

How should investors and R&D teams evaluate “EZETIMIBE + SIMVASTATIN” exposure now?

Investment interpretation

  • Treat the combination as a mature franchise. Returns are more tied to:
    • manufacturing scale,
    • contract execution,
    • reimbursement stability,
    • brand retention where relevant.
  • Pipeline-like upside exists only if a specific, registrational new indication, formulation, or combination strategy is evidenced in late-stage trials. Without that, the profile is closer to “managed business” than “binary clinical event.”

R&D interpretation

  • The path with highest probability of incremental value typically focuses on:
    • formulation improvements (stability, dose convenience),
    • adherence-focused programs,
    • observational effectiveness studies.
  • Translational innovation is less likely to be decisive because the pharmacology is already fully validated clinically and commercially.

Key Takeaways

  • EZETIMIBE + SIMVASTATIN is a mature, established oral lipid-lowering combination with a clinical role as an intensification step for LDL-C lowering.
  • Current clinical activity is predominantly post-approval and evidence maintenance, with less visible registrational phase 2/3 expansion in the open trial landscape.
  • Market growth is constrained by generic erosion and payer contracting, while demand is supported by prevalence of hypercholesterolemia and adherence advantages of fixed-dose therapy.
  • Near-term business outcomes depend more on formulary position and rebate/manufacturing execution than on a new clinical catalyst.
  • Projection should be built as a class-weighted forecast, with downside risk from displacement to other oral regimens or broader PCSK9 access and upside risk from oral step-therapy payer policies.

FAQs

1) Is EZETIMIBE + SIMVASTATIN still a priority for new phase 3 trials?

Evidence from open registries and literature patterns suggests the combination is more often studied in post-approval or non-registrational formats than as a new late-stage pivotal program, reflecting maturity of the regimen.

2) What payer dynamic most affects revenue for the fixed-dose combination?

Managed care contracting and formulary design, especially step therapy policies that dictate when patients are allowed access to higher-cost LDL-C options.

3) How does generic competition typically change the commercial outlook?

It compresses price and shifts market value toward volume share rather than premium pricing, leading to flat-to-declining revenue in markets where generic entry accelerates.

4) What is the most reliable commercial support factor?

Persistent treated prevalence plus adherence effects from fixed-dose convenience, which can stabilize share within oral lipid-lowering portfolios.

5) What would be a “real” clinical catalyst for this combination?

A clearly registered phase 3 or pivotal program tied to a new indication or a differentiating regimen that changes clinical standard-of-care and payer guidelines.


References

[1] FDA. Drug approval packages and labeling information for ezetimibe/simvastatin combination products (varies by brand and applicant). U.S. Food and Drug Administration.
[2] EMA. Product information for ezetimibe/simvastatin combination therapies (varies by authorized product). European Medicines Agency.
[3] ClinicalTrials.gov. Search results for “ezetimibe simvastatin” trial listings, including study phase and status. U.S. National Library of Medicine.
[4] AHA/ACC lipid management guidelines (most recent updates). American Heart Association / American College of Cardiology.
[5] NICE lipid modification guidance (most recent updates). National Institute for Health and Care Excellence.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.